度伐利尤单抗致不良反应的文献分析

Literature analysis of adverse reactions induced by durvalumab

目的:分析度伐利尤单抗致药品不良反应(ADR)的发生情况及临床特点,为临床安全用药提供参考。方法:通过检索PubMed、中国知网、万方和维普数据库,收集度伐利尤单抗致ADR的个案报道,并进行统计分析。结果:共检索到度伐利尤单抗致ADR的文献报道20篇,20例患者共发生31例次ADR,男性14例,女性6例,主要为60~69岁的患者(10例,50.0%),38.71%ADR发生在用药1个月内。ADR累及系统/器官主要涉及呼吸系统、皮肤及其附件、眼部等。结论:临床使用度伐利尤单抗应加强监测,警惕其ADR,尤其是药物相互作用和疾病对药物的影响,以确保临床用药安全。

Objective:To analyze the occurrence and clinical features of adverse drug reaction(ADR)induced by durvalumab,and provide references for clinical medication.Methods:Case reports of ADRs induced by durvalumab were searched and collected from databases including PubMed,CNKI,Wanfang and VIP,and were statistically analyzed.Results:A total of 31 ADRs occurred in 20 patients,including 14 males and 6 females,mainly patients aged 60–69 years(10 cases,50.0%),and 38.71%of ADRs occurred within one month.Systems/organs involved in ADRs were mainly respiratory system,skin and its accessories,eyes,etc.Conclusion:It should be closely monitored during the clinical use of durvalumab to be alert of relevant ADRs,especially drug interactions and the impact of disease on drugs,thus ensuring clinical safety drug use.